RICHMOND, VA, US, LJUBLJANA, SLOVENIA and SYDNEY, AUSTRALIA, May 22, 2014 Link here. AmpliPhi BioSciences Corporation (OTCBB: APHB), the global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, announced today that Wendy Johnson has been appointed to its Board of Directors effective May 19, 2014. Ms. Johnson will stand for election […]
Link here. RICHMOND, VA, US, LJUBLJANA, SLOVENIA and SYDNEY, AUSTRALIA, May 22, 2014 –AmpliPhi BioSciences Corporation (OTCBB: APHB), the global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, announced today that Wendy Johnson has been appointed to its Board of Directors effective May 19, 2014. Ms. Johnson will stand for election to […]
February 26, 2014. Link here. Cowen and Company 34th Annual Healthcare Conference 26th Annual ROTH Conference AmpliPhi BioSciences Corporation (OTCBB: APHB), the leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, announced that President and CEO, Philip Young will be presenting at the Cowen and Company 34^th Annual Healthcare Conference at the Boston Marriott […]
Link to press release here. RICHMOND, VA, US, COLWORTH, UK and SYDNEY, AUSTRALIA, December, 16 2013 – AmpliPhi BioSciences Corporation (OTCBB: APHB), the global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, announced today that it has entered into a definitive stock purchase agreement to raise approximately $18 million in a […]
AmpliPhi press release link here. Data presented at the 20th Biennial Evergreen International Phage Meeting, 4-9 August 2013, Evergreen State College, Olympia, WA, USA RICHMOND, Va. & SYDNEY & LONDON–(BUSINESS WIRE)–Aug. 8, 2013– AmpliPhi BioSciences Corp. (OTC: APHB) (“AmpliPhi”), the leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant bacterial infections, yesterday presented data relating to the use of bacteriophages in the […]
AmpliPhi press release link here. AmpliPhi Signs Global R&D Agreement with US Army to Develop Bacteriophage Therapies to Treat Resistant Bacterial Infections RICHMOND, VA, US, SYDNEY, AUSTRALIA, London UK, July 1, 2013 – AmpliPhi BioSciences Corporation (OTC: APHB) (“AmpliPhi”), the leader in the discovery and development of bacteriophage-based therapies to treat drug resistant bacterial infections, announced […]